Condition
Malignant Melanoma, Metastatic
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
67% success
Data Visualizations
Phase Distribution
4Total
Early P 1 (1)
P 1 (1)
P 2 (2)
Trial Status
Completed2
Terminated1
Unknown1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT01884961Phase 2Completed
Radiotherapy As an Immunological Booster in Patients with Metastatic Melanoma or Renal Cell Carcinoma Treated with High-dose Interleukin-2
NCT02591654Early Phase 1TerminatedPrimary
MRI and PET to Assess Pembrolizumab Response
NCT03715985Phase 1UnknownPrimary
Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)
NCT01363206Phase 2CompletedPrimary
Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma
Showing all 4 trials